ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Turmeric on Diabetic Nephropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01015937
Recruitment Status : Completed
First Posted : November 18, 2009
Last Update Posted : November 18, 2009
Sponsor:
Collaborator:
Shiraz University of Medical Sciences
Information provided by:
Shaheed Faghihi Hospital

Brief Summary:
The purpose of this study is to investigate whether turmeric is effective in improvement of diabetic nephropathy and in decrease in the amount of proteinuria and cytokine levels.

Condition or disease Intervention/treatment Phase
Diabetic Nephropathy Proteinuria Drug: Turmeric extract Drug: Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker Not Applicable

Detailed Description:
Diabetic nephropathy is leading cause of ESRF that many therapy recommended for it. In this study, we investigate effect of turmeric on diabetic nephropathy, thus we selected diabetic nephropathy patients and divided them into 2 groups. One group received turmeric + ACE inhibitor + Angiotensin II receptor blocker (ARB) and the second group received only ACE inhibitor + ARB.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Study Start Date : March 2008
Actual Primary Completion Date : June 2009
Actual Study Completion Date : August 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Turmeric

diabetic nephropathy patient

more than 300 mg/proteinuria

Drug: Turmeric extract
turmeric 500 mg TID for 45 days
Other Name: turmeric
Active Comparator: ACE inhibitor + ATI blocker

diabetic nephropathy

more than 300 mg/day proteinuria

Drug: Turmeric extract
turmeric 500 mg TID for 45 days
Other Name: turmeric
Drug: Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker
maximum dosage as patient tolerated for 45 days
Other Names:
  • enalapril
  • losartan




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • diabetic nephropathy
  • more than 300 mg proteinuria/day
  • age more than 18 years old

Exclusion Criteria:

  • DM type 1

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01015937


Locations
Iran, Islamic Republic of
Clinic
Shiraz, Fars, Iran, Islamic Republic of, 098
Sponsors and Collaborators
Shaheed Faghihi Hospital
Shiraz University of Medical Sciences
Investigators
Principal Investigator: maryam pakfetrat, assistant professor Shiraz nephro-urology research center

Additional Information:
Responsible Party: Office of Vice Chancellor for research in Shiraz UMS, Shiraz University of Medical Science
ClinicalTrials.gov Identifier: NCT01015937     History of Changes
Other Study ID Numbers: 3997
First Posted: November 18, 2009    Key Record Dates
Last Update Posted: November 18, 2009
Last Verified: November 2009

Keywords provided by Shaheed Faghihi Hospital:
diabetes
nephropathy
turmeric
serum IL8
serum TGFb
serumINF
urinary IL8
urine TGFb

Additional relevant MeSH terms:
Kidney Diseases
Diabetic Nephropathies
Proteinuria
Urologic Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Urination Disorders
Urological Manifestations
Signs and Symptoms
Angiotensin II
Angiotensinogen
Turmeric extract
Angiotensin-Converting Enzyme Inhibitors
Vasoconstrictor Agents
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antioxidants
Protective Agents
Physiological Effects of Drugs